The Molecular Pharming Market is benefiting from increasing research into plant-based vaccine production. Plants can potentially be engineered to produce vaccine-related proteins at scale, creating opportunities for rapid and flexible manufacturing.
Plant-based vaccine platforms have attracted attention because they can support recombinant protein production without requiring conventional animal-cell manufacturing systems. This approach may also offer advantages for certain emerging infectious-disease applications.
The development of plant-made vaccines and virus-like particles is encouraging collaboration between biotechnology companies, academic institutions, and pharmaceutical organizations. Researchers are working to improve expression levels, purification processes, and consistency.
Interest in alternative vaccine-production technologies increased significantly during recent global health emergencies, demonstrating the importance of flexible manufacturing platforms. Continued research could create additional opportunities for molecular pharming companies.
